Patients who wereM-CH⁺ with a VAF of ≥10% at baseline have increased incidence of relapse mortality when compared with other patients. At 84 months of median follow-up, patients who were M-CH⁺ with a VAF of >10% compared with who were M-CH⁺ with a VAF between 2% and 10% or who were M-CH^– presented higher incidence of relapse mortality (P < .05). n.s., not significant.